The estimated Net Worth of Sol J Barer is at least $184 Milione dollars as of 15 June 2024. Sol Barer owns over 37,598 units of Teva- Pharmaceutical Industries stock worth over $7,347,687 and over the last 21 years he sold TEVA stock worth over $176,120,292. In addition, he makes $540,003 as Independent Chairman of the Board at Teva- Pharmaceutical Industries.
Sol has made over 68 trades of the Teva- Pharmaceutical Industries stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 37,598 units of TEVA stock worth $675,260 on 15 June 2024.
The largest trade he's ever made was selling 4,098,752 units of Teva- Pharmaceutical Industries stock on 5 December 2019 worth over $532,838. On average, Sol trades about 110,558 units every 41 days since 2003. As of 15 June 2024 he still owns at least 409,114 units of Teva- Pharmaceutical Industries stock.
You can see the complete history of Sol Barer stock trades at the bottom of the page.
Dr. Sol J. Barer Ph.D. serves as Independent Chairman of the Board of the Company. He also serves as an advisor to the Israel Biotech Fund. From 1987 to 2011, he served in top leadership roles at Celgene Corporation, including as Executive Chairman from 2010 to 2011, Chairman and CEO from 2007 to 2010, CEO from 2006 to 2010, President and Chief Operating Officer from 1994 to 2006 and President from 1993 to 1994. Prior to that, he was a founder of the biotechnology group at the chemical company Celanese Corporation, which was later spun off as Celgene. Dr. Barer serves on the board of directors of Cerecor, Inc. (formerly Aevi Genomic Medicine, Inc.) and on the board of directors of Contrafect as lead director. He served as Chairman of the Board of Edge Therapeutics from 2013 to March 2019, on the board of Aegerion Pharmaceuticals from 2011 to 2016, on the board of Amicus Therapeutics from 2009 to February 2017 and as Chairman of the Board of InspireMD from 2011 to June 2017. Dr. Barer is Founding Chair of the Center for Innovation and Discovery at the Hackensack Meridian Medical School. Dr. Barer received his Ph.D. in organic and physical chemistry from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York.
As the Independent Chairman of the Board of Teva- Pharmaceutical Industries, the total compensation of Sol Barer at Teva- Pharmaceutical Industries is $540,003. There are 10 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of $11,596,600.
Sol Barer is 72, he's been the Independent Chairman of the Board of Teva- Pharmaceutical Industries since 2017. There are 1 older and 28 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.
Sol's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks e Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include: